AstraZeneca has announced that its LATIFY phase III trial didn't work out as planned. The trial was testing ceralasertib mixed with Imfinzi (durvalumab) against the usual docetaxel treatment for patients with non-small cell lung cancer (NSCLC) that h
Bharat Biotech signs a tech transfer deal with Biofabri to develop and supply the MTBVAC tuberculosis vaccine, supporting global TB control and Phase III trials.
Takeda’s experimental AI-crafted psoriasis pill, zasocitinib, achieved impressive results in two pivotal Phase?3 trials, marking a major milestone in the treatment of plaque psoriasis.Compared to placebo and active comparators, the once-per-day...
Sanofi said today that tolebrutinib failed to meet its primary endpoint in the PERSEUS phase 3 study in people with primary progressive multiple sclerosis (PPMS), a form of the disease that affects about 10% of the overall MS population...
Indoco Remedies Limited has received a key regulatory clearance from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients operations, strengthening its position in the global pharmaceutical supply chain...
Piramal Pharma drew attention today as the US FDA wrapped up a general Good Manufacturing Practices inspection at the company’s Lexington, Kentucky site. The review, held from December 3 to December 10, 2025, ended with a Form 483 containing...
Roche today released new three-year data showing that Columvi in combination with GemOx continues to deliver major survival gains for people with relapsed or refractory DLBCL who are not candidates for transplant.After a median 35.1-month...
Pfizer is drawing global attention today with new Phase 3 data showing its investigational therapy HYMPAVZI could shift treatment for people with hemophilia A or B who develop inhibitors. These patients often face some of the toughest treatment...
.png)
Takeda has signed a license and collaboration agreement with Innovent Biologics and satisfied all the terms and transitioned the collaboration to the implementation phase. The deal that was initially unveiled in October of 2025 enhances the...
The Establishment Inspection Report (EIR) issued to Zydus Lifesciences by the U.S. Food and Drug Administration (USFDA) concerning the GMP follow-up inspection at its injectable manufacturing facility in Jarod, Vadodara. This audit was carried out be
.jpg)
.jpg)
, CDSCO.jpg)